Breast Cancer

The assistant professor from the University of Michigan talked about personalizing radiation treatment in patients with breast cancer and how genomic signatures can be used to identify the radiation needs of patients.

The cancer risk and prevention expert discussed germline testing and the benefits it lends to patients with breast cancer.

The professor of radiation oncology discussed these tailored treatments for when patients receive neoadjuvant chemotherapy, and they get a complete pathologic response.

The hematology and medical oncology expert described the implementation of biosimilars into treating patients with breast cancer.

Breast reconstruction improves quality of life, but providers must be aware of the risks and benefits of each reconstruction approach in the setting of postmastectomy radiotherapy.

Five years of treatment with anastrozole safely and effectively prevented breast cancer recurrence in high-risk postmenopausal women at 10.9 years of follow-up.

T-DXd demonstrated improved and durable response rates in heavily pretreated patients with advanced HER2-positive breast cancer.

The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis.

Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer.

The Food and Drug Administration approved the first generic for everolimus, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

Nancy Davidson, MD, from Seattle Cancer Care Alliance and Fred Hutchinson Research Center, discussed advancements in breast cancer.

Research suggests that there is an association between breast cancer risk and the use of chemical straighteners and permanent hair dyes.

The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.

Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer.

The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.

Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24.

Oncotype DX® Breast Recurrence Scores from the National Cancer Database indicated that a lower threshold is needed for male patients with early stage ER-positive breast cancer to predict mortality.

Fergus Couch, PhD, from the Mayo Clinic, discusses with CancerNetwork about the new research with the CARRIERS study for African American patients with breast cancer.

A quality improvement study indicated that nudges in the electronic health record were associated with a significant increase in clinician ordering of screening tests for breast and colorectal cancer.

The US Food and Drug Administration recently approved alpelisib plus fulvestrant for the treatment of metastatic or otherwise advanced breast cancer.

Highlights of breast cancer advances at the ESMO Congress.

Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Biosimilars have shown to be cost-effective treatments in oncology and hematology, according to Jacopo Giuliani, MD.

MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.